BRIEF—Fresenius launches US alternative to Ultiva

Fresenius Kabi, a company specializing in medicines and technologies for infusion, transfusion and clinical nutrition, has announced the US availability of injectable remifentanil hydrochloride, an opioid analgesic drug.

The Germany-headquartered company has billed remifentanil as a first-to-market and lower cost alternative to Mylan’s Ultiva for anesthesia clinicians.